Hologic (NASDAQ:HOLX) had its target price lifted by stock analysts at Wells Fargo & Co from $63.00 to $80.00 in a research report issued on Thursday, The Fly reports. The firm presently has an “overweight” rating on the medical equipment provider’s stock. Wells Fargo & Co‘s price objective would suggest a potential upside of 14.65% from the stock’s current price.

Other equities analysts have also issued reports about the stock. TheStreet upgraded shares of Hologic from a “c+” rating to a “b-” rating in a report on Thursday, May 14th. Morgan Stanley upped their price objective on Hologic from $53.00 to $55.00 and gave the company an “equal weight” rating in a report on Tuesday, June 9th. Stifel Nicolaus cut their target price on Hologic from $52.00 to $45.00 and set a “hold” rating for the company in a research note on Wednesday, April 8th. SVB Leerink lifted their target price on Hologic from $66.00 to $80.00 and gave the company an “outperform” rating in a research report on Thursday. Finally, Citigroup boosted their price objective on shares of Hologic from $63.00 to $85.00 and gave the company a “buy” rating in a report on Thursday. One investment analyst has rated the stock with a sell rating, six have given a hold rating and thirteen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $64.28.

NASDAQ:HOLX opened at $69.78 on Thursday. The stock has a 50 day moving average price of $57.42 and a 200 day moving average price of $50.06. The stock has a market cap of $18.05 billion, a PE ratio of 28.25, a P/E/G ratio of 3.69 and a beta of 1.47. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.04 and a current ratio of 1.47. Hologic has a one year low of $26.49 and a one year high of $70.35.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.37. The business had revenue of $822.90 million during the quarter, compared to the consensus estimate of $622.96 million. Hologic had a return on equity of 31.40% and a net margin of 20.03%. The company’s revenue for the quarter was down 3.4% on a year-over-year basis. During the same period last year, the company earned $0.63 EPS. As a group, analysts predict that Hologic will post 2.3 earnings per share for the current fiscal year.

In other Hologic news, CEO Stephen P. Macmillan sold 190,996 shares of the stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $50.97, for a total value of $9,735,066.12. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Peter J. Valenti III sold 10,493 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $54.07, for a total transaction of $567,356.51. The disclosure for this sale can be found here. Insiders sold 243,932 shares of company stock worth $12,507,250 in the last three months. 1.00% of the stock is currently owned by corporate insiders.

Institutional investors have recently modified their holdings of the company. State Street Corp lifted its position in Hologic by 1.2% in the first quarter. State Street Corp now owns 11,584,851 shares of the medical equipment provider’s stock valued at $406,628,000 after acquiring an additional 137,837 shares during the last quarter. Nuveen Asset Management LLC grew its holdings in shares of Hologic by 11.3% during the first quarter. Nuveen Asset Management LLC now owns 3,548,837 shares of the medical equipment provider’s stock worth $124,564,000 after buying an additional 359,054 shares during the last quarter. Norges Bank purchased a new position in shares of Hologic during the fourth quarter worth about $153,506,000. Legal & General Group Plc raised its stake in Hologic by 3.2% during the 1st quarter. Legal & General Group Plc now owns 2,081,642 shares of the medical equipment provider’s stock valued at $73,222,000 after acquiring an additional 64,794 shares during the last quarter. Finally, AQR Capital Management LLC raised its stake in Hologic by 68.4% during the 1st quarter. AQR Capital Management LLC now owns 1,689,040 shares of the medical equipment provider’s stock valued at $59,285,000 after acquiring an additional 686,101 shares during the last quarter. Institutional investors and hedge funds own 92.34% of the company’s stock.

About Hologic

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Featured Story: What is the Dow Jones Industrial Average (DJIA)?

The Fly

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.